Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) shares reached a new 52-week high on Wednesday . The stock traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares traded. The stock had previously closed at $52.83.
Analyst Ratings Changes
Separately, HC Wainwright raised shares of Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
View Our Latest Report on Basilea Pharmaceutica
Basilea Pharmaceutica Price Performance
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Profitably Trade Stocks at 52-Week Highs
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Why Invest in High-Yield Dividend Stocks?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
